1. Home
  2. ALKT vs NUVB Comparison

ALKT vs NUVB Comparison

Compare ALKT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$18.95

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.96

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
NUVB
Founded
2007
2018
Country
United States
United States
Employees
N/A
298
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ALKT
NUVB
Price
$18.95
$4.96
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$28.57
$11.38
AVG Volume (30 Days)
1.5M
4.3M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$152,159,000.00
N/A
Revenue This Year
$21.85
$203.82
Revenue Next Year
$16.90
$58.18
P/E Ratio
N/A
N/A
Revenue Growth
35.68
N/A
52 Week Low
$14.11
$1.57
52 Week High
$31.18
$9.75

Technical Indicators

Market Signals
Indicator
ALKT
NUVB
Relative Strength Index (RSI) 69.32 57.70
Support Level $15.16 $4.07
Resistance Level $19.21 $5.23
Average True Range (ATR) 0.79 0.26
MACD 0.20 0.03
Stochastic Oscillator 91.13 89.06

Price Performance

Historical Comparison
ALKT
NUVB

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: